We are live on ! Find out more
BLRX

BioLineRX
BLRX

14 hedge funds and large institutions have $208K invested in BioLineRX in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

359% more capital invested

Capital invested by funds: $45.2K → $208K (+$162K)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

8% more funds holding

Funds holding: 13 → 14 (+1)

1.07% more ownership

Funds ownership: 0.45% → 1.52% (+1.1%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
4
Closed
3
Calls
$121K
Puts
–
Net Calls
+$121K
Net Calls Change
+$97K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$89.6K
2
Renaissance Technologies
Renaissance Technologies
New York
+$44.7K
3
Citadel Advisors
Citadel Advisors
Florida
+$42.9K
4
Wells Fargo
Wells Fargo
California
+$725
5
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$362

Top Sellers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
-$25.3K
2
Citigroup
Citigroup
New York
-$5.01K
3
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$3.77K
4
UBS Group
UBS Group
Switzerland
-$1.24K
5
Morgan Stanley
Morgan Stanley
New York
-$230

BLRX Hedge Fund Activity: Q2 2026 in Review

14 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2026, worth a combined $208K — up 359% from $45.2K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BLRX positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $89.6K. The largest seller was XTX Topco, exiting entirely with an estimated $25.3K sold.

  • 14 institutional investors held BioLineRX (BLRX) as of Q2 2026, up from 13 in Q1 2026.
  • Funds reported $208K of BioLineRX stock for Q2 2026, up 359% quarter-over-quarter.
  • 4 funds opened new BioLineRX positions in Q2 2026 and 3 closed out, a net change of +1 holder.
  • The largest BioLineRX buyer in Q2 2026 was Susquehanna International Group, an estimated $89.6K added.
  • The largest BioLineRX seller in Q2 2026 was XTX Topco, an estimated $25.3K sold.

Based on aggregated 13F filings for Q2 2026.